PEGylated Nanoliposomes Encapsulated with Anticancer Drugs for Breast and Prostate Cancer Therapy: An Update

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2025 Feb 26

PMID 40006557

Authors

Sijongesonke Peter

Vuyolwethu Khwaza

Sibusiso Alven

Tobeka Naki

Blessing Atim Aderibigbe

Affiliations

Soon will be listed here.

Abstract

There are different types of cancer treatments, including surgery, radiotherapy, and chemotherapy. However, the complexity of cancer has resulted in treatment challenges to medicinal scientists and a socio-economic burden to the public health system globally. The pharmacological limitations associated with the current conventional anticancer drugs include lack of specificity, poor bioavailability, toxicity, drug resistance, and poor delivery mechanisms, which make cancer treatment challenging. Thus, the number of cancer cases is escalating rapidly, especially breast and prostate cancer in women and men, respectively. The application of nanoformulations is gaining momentum for treating different cancer types. However, they also exhibit challenges that must be addressed for effective cancer treatment. Nanoliposomes are nanoformulations that are widely explored for cancer treatment with interesting therapeutic outcomes. They have been functionalized with PEG to further improve their therapeutic outcomes. Hence, this review provides an update on PEGylated nanoliposomes loaded with anticancer drugs for the treatment of breast and prostate cancer, focusing on pre-clinical studies published in the last decade (2015 to 2024) to reflect the recent advancements made in the design of PEGylation nanoliposomes. Highlights of the clinically and commercially available PEGylation nanoliposomes are also presented in this review.

References

Sherman M, Williams L, Sobczyk M, Michaels S, Saifer M . Role of the methoxy group in immune responses to mPEG-protein conjugates. Bioconjug Chem. 2012; 23(3):485-99. PMC: 3309606. DOI: 10.1021/bc200551b. View

Shahbazian S, Akbarzadeh A, Torabi S, Omidi M . Anti-cancer activity of pegylated liposomal trans-anethole on breast cancer cell lines MCF-7 and T47D. Biotechnol Lett. 2015; 37(7):1355-9. DOI: 10.1007/s10529-015-1813-5. View

Nosova A, Koloskova O, Nikonova A, Simonova V, Smirnov V, Kudlay D . Diversity of PEGylation methods of liposomes and their influence on RNA delivery. Medchemcomm. 2019; 10(3):369-377. PMC: 6457174. DOI: 10.1039/c8md00515j. View

Zhang P, Fu C, Hu Y, Dong C, Song Y, Song E . C6-ceramide nanoliposome suppresses tumor metastasis by eliciting PI3K and PKCζ tumor-suppressive activities and regulating integrin affinity modulation. Sci Rep. 2015; 5:9275. PMC: 4366857. DOI: 10.1038/srep09275. View

Ahmed M, Anwer M, Fatima F, Aldawsari M, Alalaiwe A, Alali A . Boosting the Anticancer Activity of Sunitinib Malate in Breast Cancer through Lipid Polymer Hybrid Nanoparticles Approach. Polymers (Basel). 2022; 14(12). PMC: 9227860. DOI: 10.3390/polym14122459. View

Chiani M, Norouzian D, Shokrgozar M, Azadmanesh K, Najmafshar A, Mehrabi M . Folic acid conjugated nanoliposomes as promising carriers for targeted delivery of bleomycin. Artif Cells Nanomed Biotechnol. 2017; 46(4):757-763. DOI: 10.1080/21691401.2017.1337029. View

Shao L, Kahraman N, Yan G, Wang J, Ozpolat B, Ittmann M . Targeting the TMPRSS2/ERG fusion mRNA using liposomal nanovectors enhances docetaxel treatment in prostate cancer. Prostate. 2019; 80(1):65-73. PMC: 6925833. DOI: 10.1002/pros.23918. View

Al-Samydai A, Alshaer W, Al-Dujaili E, Azzam H, Aburjai T . Preparation, Characterization, and Anticancer Effects of Capsaicin-Loaded Nanoliposomes. Nutrients. 2021; 13(11). PMC: 8620281. DOI: 10.3390/nu13113995. View

Mohamed M, Lila A, Shimizu T, Alaaeldin E, Hussein A, Sarhan H . PEGylated liposomes: immunological responses. Sci Technol Adv Mater. 2019; 20(1):710-724. PMC: 6598536. DOI: 10.1080/14686996.2019.1627174. View

10.

Vakili-Ghartavol R, Rezayat S, Faridi-Majidi R, Sadri K, Jaafari M . Optimization of Docetaxel Loading Conditions in Liposomes: proposing potential products for metastatic breast carcinoma chemotherapy. Sci Rep. 2020; 10(1):5569. PMC: 7101339. DOI: 10.1038/s41598-020-62501-1. View

11.

Mirzavi F, Barati M, Vakili-Ghartavol R, Karimi Roshan M, Mashreghi M, Soukhtanloo M . Pegylated liposomal encapsulation improves the antitumor efficacy of combretastatin A4 in murine 4T1 triple-negative breast cancer model. Int J Pharm. 2021; 613:121396. DOI: 10.1016/j.ijpharm.2021.121396. View

12.

Shimizu T, Ichihara M, Yoshioka Y, Ishida T, Nakagawa S, Kiwada H . Intravenous administration of polyethylene glycol-coated (PEGylated) proteins and PEGylated adenovirus elicits an anti-PEG immunoglobulin M response. Biol Pharm Bull. 2012; 35(8):1336-42. DOI: 10.1248/bpb.b12-00276. View

13.

Khan A, Allemailem K, Almatroodi S, Almatroudi A, Rahmani A . Recent strategies towards the surface modification of liposomes: an innovative approach for different clinical applications. 3 Biotech. 2020; 10(4):163. PMC: 7062946. DOI: 10.1007/s13205-020-2144-3. View

14.

Tagde P, Najda A, Nagpal K, Kulkarni G, Shah M, Ullah O . Nanomedicine-Based Delivery Strategies for Breast Cancer Treatment and Management. Int J Mol Sci. 2022; 23(5). PMC: 8911433. DOI: 10.3390/ijms23052856. View

15.

Hoffman A . The origins and evolution of "controlled" drug delivery systems. J Control Release. 2008; 132(3):153-63. DOI: 10.1016/j.jconrel.2008.08.012. View

16.

Golkar N, Tamaddon A, Samani S . Effect of lipid composition on incorporation of trastuzumab-PEG-lipid into nanoliposomes by post-insertion method: physicochemical and cellular characterization. J Liposome Res. 2015; 26(2):113-25. DOI: 10.3109/08982104.2015.1048692. View

17.

Tian J, Chi C, Bian G, Xing D, Guo F, Wang X . PSMA conjugated combinatorial liposomal formulation encapsulating genistein and plumbagin to induce apoptosis in prostate cancer cells. Colloids Surf B Biointerfaces. 2021; 203:111723. DOI: 10.1016/j.colsurfb.2021.111723. View

18.

Song Y, Yuan Y, Shi X, Che Y . Improved drug delivery and anti-tumor efficacy of combinatorial liposomal formulation of genistein and plumbagin by targeting Glut1 and Akt3 proteins in mice bearing prostate tumor. Colloids Surf B Biointerfaces. 2020; 190:110966. DOI: 10.1016/j.colsurfb.2020.110966. View

19.

Rustad E, von Hofsten S, Kumar R, Laensman E, Berge G, Skalko-Basnet N . The pH-Responsive Liposomes-The Effect of PEGylation on Release Kinetics and Cellular Uptake in Glioblastoma Cells. Pharmaceutics. 2022; 14(6). PMC: 9227832. DOI: 10.3390/pharmaceutics14061125. View

20.

Zhang W, Song Y, Eldi P, Guo X, Hayball J, Garg S . Targeting prostate cancer cells with hybrid elastin-like polypeptide/liposome nanoparticles. Int J Nanomedicine. 2018; 13:293-305. PMC: 5768422. DOI: 10.2147/IJN.S152485. View